Dianthus Therapeutics (DNTH) SEC Filings & 10K Form

$24.85
+0.56 (+2.31%)
(As of 11:30 AM ET)

Recent Dianthus Therapeutics SEC Filings

DateFilerForm TypeView
05/09/2024
3:20 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/09/2024
3:08 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/11/2024
3:05 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form DEF 14A
04/11/2024
3:09 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form DEFA14A
04/11/2024
3:10 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form ARS
04/01/2024
5:34 PM
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
Fairmount Funds Management LLC (Filed by)
Form SC 13D/A
04/01/2024
5:21 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Fairmount Funds Management LLC (Reporting)
Kiselak Tomas (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2024
11:15 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form EFFECT
03/21/2024
4:02 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form S-1/A
03/21/2024
4:10 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/02/2024
3:32 PM
BCLS Fund III Investments, LP (Filed by)
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
Form SC 13G
01/31/2024
11:11 AM
Avidity Partners Management LP (Filed by)
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
Form SC 13D
01/24/2024
6:02 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Fairmount Funds Management LLC (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/24/2024
6:04 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
MOULDER LEON O JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/24/2024
5:55 PM
Avidity Partners Management LLC (0001993910) (Reporting)
Avidity Partners Management LP (Reporting)
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Gregory Michael David (Reporting)
Meng Lei (Reporting)
Witzke David Roy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/24/2024
4:26 PM
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
Fairmount Funds Management LLC (Filed by)
Form SC 13D/A
01/22/2024
6:34 AM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2024
7:02 AM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/21/2023
4:08 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form S-1/A
11/13/2023
8:02 AM
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
FMR LLC (Filed by)
Form SC 13G
10/25/2023
3:15 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/04/2023
3:55 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
09/28/2023
4:09 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Fairmount Funds Management LLC (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2023
3:15 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Randhawa Simrat (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/21/2023
3:34 PM
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
Viridian, LLC (Filed by)
Form SC 13D
09/21/2023
3:23 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Fairmount Funds Management LLC (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/21/2023
3:32 PM
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
Fairmount Funds Management LLC (Filed by)
Form SC 13D
09/21/2023
3:15 PM
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
Form SC 13G
09/21/2023
3:15 PM
5AM Partners VII, LLC (Filed by)
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
Form SC 13G
09/20/2023
8:50 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form 8-K/A
09/15/2023
3:56 PM
Atlas Venture Fund X, L.P. (Filed by)
Dianthus Therapeutics, Inc. /DE/ (Subject)
Dianthus Therapeutics (Subject)
Form SC 13D/A
09/13/2023
8:56 PM
Avidity Partners Management LP (Reporting)
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Meng Lei (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2023
8:31 PM
Avidity Partners Management LP (Reporting)
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Meng Lei (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/13/2023
7:45 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Savitz Ryan (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/13/2023
7:46 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
MOULDER LEON O JR (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/13/2023
7:46 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Violin Jonathan (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/13/2023
7:47 PM
CARR EDWARD (Reporting)
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
09/13/2023
7:48 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Veness Adam M (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/13/2023
7:50 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Randhawa Simrat (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/13/2023
7:51 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Garcia Marino (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/13/2023
7:52 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Soteropoulos Paula (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI Breakthroughs (Ad)

While gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.

Click to watch this device in action
09/13/2023
7:55 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Fairmount Funds Management LLC (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/13/2023
8:13 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
MOULDER LEON O JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2023
8:14 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
McGeorge Anne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2023
8:16 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Soteropoulos Paula (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2023
8:17 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Lawton Alison Frances (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2023
8:17 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Fairmount Funds Management LLC (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2023
8:25 PM
Dianthus Therapeutics, Inc. /DE/ (Issuer)
Dianthus Therapeutics (Issuer)
Violin Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2023
3:05 PM
Dianthus Therapeutics, Inc. /DE/ (Filer)
Dianthus Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/08/2023
4:19 PM
Magenta Therapeutics, Inc. (Filer)
Dianthus Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/31/2023
8:00 AM
Magenta Therapeutics, Inc. (Subject)
Dianthus Therapeutics (Subject)
Form 425
08/03/2023
7:01 AM
Magenta Therapeutics, Inc. (Filer)
Dianthus Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/01/2023
11:15 PM
Magenta Therapeutics, Inc. (Filer)
Dianthus Therapeutics (Filer)
Form EFFECT
08/01/2023
3:42 PM
Magenta Therapeutics, Inc. (Filer)
Dianthus Therapeutics (Filer)
Form 424B3
07/17/2023
8:30 AM
Magenta Therapeutics, Inc. (Filer)
Dianthus Therapeutics (Filer)
Form S-4/A
06/22/2023
4:23 PM
Magenta Therapeutics, Inc. (Filer)
Dianthus Therapeutics (Filer)
Form S-4/A
05/15/2023
7:39 AM
Magenta Therapeutics, Inc. (Filer)
Dianthus Therapeutics (Filer)
Form S-4
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:DNTH) was last updated on 5/13/2024 by MarketBeat.com Staff

From Our Partners